NCT05285904 - Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Multiple Sclerosis

Interventions

OTHER

Ofatumumab

Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (13)

1011

Novartis Investigative Site, Lausanne

1196

Novartis Investigative Site, Gland

3010

Novartis Investigative Site, Bern

4001

Novartis Investigative Site, Basel

5405

Novartis Investigative Site, Baden

6000

Novartis Investigative Site, Lucerne

6004

Novartis Investigative Site, Lucerne

6006

Novartis Investigative Site, Lucerne

6900

Novartis Investigative Site, Lugano

7320

Novartis Investigative Site, Sargans

8001

Novartis Investigative Site, Zurich

8006

Novartis Investigative Site, Zurich

8091

Novartis Investigative Site, Zurich